Healthtech Series B Investors & VC Firms
1028 firms in this list, with a median first check of $540K. 256 of them lead rounds. Generated from verified public data and updated continuously.
SJF Ventures
DurhamSeries A–Late Stage$1M – $10M
15 people
DAYLI Partners
SeoulSeed–Late Stage
13 people
Novartis Venture Fund
BaselSeed–Growth$5M – $25M
21 people
T. Rowe Price
BaltimoreSeed–Series C
6 people
Main Sequence Ventures
SydneyPre-Seed–Series B
25 people
Penny Jar Capital Venture
Palo AltoPre-Seed–Series B
33 people
Parkwalk Advisors
LondonSeed–Series C
30 people
Energy & Environment Investment
TokyoPre-Seed–Growth
18 people
UOB Venture Management
SingaporeSeed–Growth$10M – $50M
30 people
Kaiser Permanente Ventures
San FranciscoSeed–Growth$2M – $5M
13 people
Primo Ventures
MilanPre-Seed–Growth$1.1M
17 people
Gingerbread Capital
New YorkSeed–Series B$100K – $10M
9 people
83North
LondonSeed–Late Stage$100K – $10M
4 people
coparion
CologneSeed–Growth$550K – $16.5M
26 people
B4 Capital
Seed–Late Stage$10M – $50M
2 people
Permira
St Peter PortSeries B–Late Stage
40 people
International Finance Corporation
Washington D.C.Series A–Late Stage
24 people
KT investment Inc.
SeoulPre-Seed–Series B
Cox Enterprises
AtlantaSeed–Late Stage
34 people
TLV Partners
Tel AvivSeed–Series B$2M – $8M
17 people
Vox Capital
São PauloSeed–Series B$90K – $6M
29 people
Dreamers VC
El SegundoSeed–Series B$500K – $5M
10 people
BioGeneration Ventures
NaardenPre-Seed–Late Stage
26 people
VantagePoint Capital Partners
Silicon ValleySeed–Growth$2M – $100M
18 people
Related lists
Healthtech Investors & VC Firms (4191)Healthtech Seed Investors & VC Firms (3233)Series B Investors & VC Firms (2946)Healthtech Investors & VC Firms in North America (2666)Healthtech Investors & VC Firms in United States (2437)Healthtech Series A Investors & VC Firms (2310)Series B Investors & VC Firms in North America (1736)Series B Investors & VC Firms in United States (1571)Healthtech Pre-Seed Investors & VC Firms (1468)Healthtech Investors & VC Firms in Europe (1358)
Data sourced from public filings and firms' own websites — see our methodology.






























































































